Investors Update – December 2021

AAGL Convention

The company presented at the 2021 AAGL convention (Biggest GYN surgery convention) to leading global medical device companies. The meeting participants were VP`s and directors of companies that are potantial buyers for Ark's technology. Several companies expressed interest and further discussions will take place in the coming month.



U.S. Usability Tests:

As part of the FDA requirements, the company has successfully performed a training and usability test in Yale medical school and additional medical centers in Connecticut. Following the trial several physicians expressed their desire to be LapBox first users.



FDA Submission:

The FDA testing is 90% completed as final results are arriving from laboratories and testing sites.
All test are successful and file submisson is expected during January for the manual morcellaton approval.
For power morcelaton approval, additonal usabilty tesitng will begin in January and expected to be completed by March.

Patents:

Ark has received its first patent approval in the US for the LapBox technology.
Currently two more patents are in national phase waiting to be examined and a fourth patent has started its PCT stage.

Funding

Ark was chosen to receive a non-dilutive grant from the Israeli Innovation Authority (IIA) for $0.6M. This is an acknowledgement of the successful progress the company reached so far and the potential the examiners found in the company's future.

Website:

Ark has launched its new website: https://ark-surgical.com/ dedicated for physicians, medical staff and patients. The company LinkedIn page is: https://www.linkedin.com/company/ark-surgical

Future:

- Ark continues to work on its market penetration plan for the soft launch and is performing a market research study with physicians and hospital administrators that will be concluded in January.
- The company is upgrading its manufacturing and testing capabilities in preparation to the soft launch.
- Ark is working towards receiving ISO 13485 certificate that will strengthen its quality control process to ensure successful and repeatable manufacturing of its devices.
- The company will conduct follow up meetings with the global companies.
- The company will start preparation for a round B funding that will be needed to support sales following the soft launch - in case the meeting with the companies will indicate it is needed.

ARK SURGICAL

di El Haj 13, Nazareth, 17111, Israel // F: +972-4-6564129 // M: +972-52-359-4441 // @: info@ark-surical.com